NEO (NeoGenomics, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by NEO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Alicia C Olivo | EVP, GC & Business Development | F | — | — |
| 2026-08-25 | Warren Stone | Pres & Chief Operating Officer | MIXED | — | — |
| 2026-08-06 | Greg D Aunan | Chief Accounting Officer | Sell | — | — |
| 2026-08-06 | Greg D Aunan | Chief Accounting Officer | Sell | — | — |
| 2026-06-25 | Carolyn S Starrett | Director | A | — | — |
| 2026-06-17 | LYNN A. TETRAULT | Director | Sell | — | — |
| 2026-06-11 | LYNN A. TETRAULT | Director | Sell | — | — |
| 2026-06-03 | Marjorie C Green | Director | M | — | — |
| 2026-06-03 | David Brian Perez | Director | M | — | — |
| 2026-06-03 | STEPHEN M KANOVSKY | Director | M | — | — |
| 2026-06-03 | LYNN A. TETRAULT | Director | M | — | — |
| 2026-06-03 | Michael Aaron Kelly | Director | M | — | — |
| 2026-06-03 | John P. Kenny | Director | M | — | — |
| 2026-06-03 | Felicia Williams | Director | M | — | — |
| 2026-06-03 | Neil Gunn | Director | M | — | — |
| 2026-05-13 | Alicia C Olivo | EVP, GC & Business Development | MIXED | — | — |
| 2026-05-13 | Warren Stone | Pres & Chief Operating Officer | MIXED | — | — |
| 2026-05-05 | Warren Stone | Pres & Chief Operating Officer | MIXED | — | — |
| 2026-05-05 | Alicia C Olivo | EVP, GC & Business Development | F | — | — |
| 2026-05-05 | Greg D Aunan | Chief Accounting Officer | MIXED | — | — |
| 2026-04-03 | Anthony P. Zook | Chief Executive Officer | MIXED | — | — |
| 2026-04-03 | Warren Stone | Pres & Chief Operating Officer | MIXED | — | — |
| 2026-03-03 | Anthony P. Zook | Chief Executive Officer | A | — | — |
| 2026-03-03 | Greg D Aunan | Chief Accounting Officer | A | — | — |
| 2026-03-03 | Alicia C Olivo | EVP, GC & Business Development | A | — | — |
| 2026-03-03 | Warren Stone | Pres & Chief Operating Officer | A | — | — |
| 2026-02-24 | Greg D Aunan | Chief Accounting Officer | MIXED | — | — |
| 2026-02-24 | Warren Stone | Pres & Chief Operating Officer | MIXED | — | — |
| 2026-02-24 | Alicia C Olivo | EVP, GC & Business Development | MIXED | — | — |
| 2026-02-24 | Jeffrey Scott Sherman | Chief Financial Officer | MIXED | — | — |
| 2026-01-21 | Warren Stone | Pres & Chief Operating Officer | Sell | — | — |
| 2026-01-15 | Warren Stone | Pres & Chief Operating Officer | MIXED | — | — |
| 2026-01-15 | Alicia C Olivo | EVP, GC & Business Development | MIXED | — | — |
| 2026-01-05 | John P. Kenny | Director | A | — | — |
| 2025-12-09 | Jeffrey Scott Sherman | Chief Financial Officer | F | — | — |
| 2025-12-03 | Warren Stone | Pres & Chief Operating Officer | F | — | — |
| 2025-11-28 | Alicia C Olivo | EVP, GC & Business Development | MIXED | — | — |
| 2025-10-20 | Alicia C Olivo | EVP, GC & Business Development | Sell | — | — |
| 2025-09-03 | Alicia C Olivo | EVP, GC & Business Development | F | — | — |
| 2025-08-06 | Jeffrey Scott Sherman | Chief Financial Officer | Buy | — | — |
| 2025-08-06 | Anthony P. Zook | Chief Executive Officer | Buy | — | — |
| 2025-08-05 | Alicia C Olivo | EVP, GC & Business Development | F | — | — |
| 2025-06-24 | Marjorie C Green | Director | A | — | — |
| 2025-06-03 | ALISON L. HANNAH | Director | M | — | — |
| 2025-06-03 | Anthony P. Zook | Chief Executive Officer | MIXED | — | — |
| 2025-06-03 | STEPHEN M KANOVSKY | Director | M | — | — |
| 2025-06-03 | David Brian Perez | Director | M | — | — |
| 2025-06-03 | Neil Gunn | Director | M | — | — |
| 2025-06-03 | Michael Aaron Kelly | Director | M | — | — |
| 2025-06-03 | Elizabeth Floegel | Director | M | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 10,835,145 | — |
| — | Chairman and CEO | 2,483,797 | — |
| — | Director | 1,821,650 | — |
| — | Chief Executive Officer | 655,652 | — |
| — | Executive VP of Finance | 501,251 | — |
| — | Chief Executive Officer | 368,051 | — |
| — | President, Clinical Services | 266,638 | — |
| — | President & COO, Lab Ops | 264,996 | — |
| — | Chief Financial Officer | 218,986 | — |
| — | Pres & Chief Operating Officer | 192,138 | — |
| — | Chief Financial Officer | 191,548 | — |
| — | Director | 176,126 | — |
| — | Chief Medical Officer | 165,992 | — |
| — | Chief Strategy Officer | 158,684 | — |
| — | Chief Executive Officer | 152,011 | — |
| — | Chief Legal Officer | 147,396 | — |
| — | Director | 131,023 | — |
| — | Director | 130,975 | — |
| — | Chief Medical Officer | 130,847 | — |
| — | President Advanced Diagnostics | 128,921 | — |
| — | Chf Ops Off, Pres, Informatics | 109,755 | — |
| — | Director | 93,115 | — |
| — | EVP, GC & Business Development | 90,875 | — |
| — | CIO | 86,499 | — |
| — | Chief Scientific Officer | 82,673 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NEO quote page; the site-wide leaderboard is on the insider transactions hub.